Robert W. Sprung
Robert W. Sprung has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
- Arun Renganathan
Department of Psychiatry, Washington University in St Louis, St Louis, USA
57 shared publications - Cody Weimholt
Washington University in St. Louis 19 St.Louis, MO
57 shared publications - Duminduni H. Angappulige
Division of Urologic Surgery, Washington University in St. Louis, St. Louis, Missouri
57 shared publications - Duy T. Nguyen
Department of Cancer Biology, Mayo Clinic College of Medicine, Jacksonville, FL, USA; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, MN, USA
57 shared publications - Eric H. Kim
University of Nevada Reno 17
57 shared publications - Gerald L. Andriole
Siteman Cancer Center, Barnes Jewish Hospital and Washington University School of Medicine, St. Louis, Missouri
57 shared publications
Latest Publications
- Open Access
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Missense Mutations in Myc Box I Influence Nucleocytoplasmic Transport to Promote Leukemogenesis
Supplementary Figure 6. (A-B) Bar graphs of the distribution of white blood cells (WBC) counts (1000/microliter), hemoglobin (Hb, grams/deciliter) and platelets (1000/microliter) in MycT58N/+ and Myc+/+mice at 8 and 12 weeks of age. None of the differences are statistically significant. (C) Bar graphs of the distribution of weight in 8-12 weeks old males (left panel) and females (right panel) MycT58N/+and Myc+/+showing no significant differences across genotype. (D-E) Bar graphs of the distribution of stem and progenitor cells in the bone marrow compartment of 6-8 weeks old MycT58N/+ and Myc+/+ as determined by flow cytometry analysis. None of the differences are statistically significant. (F) Confocal images of HSPCs isolated from healthy, 6 months old, MycT58N/+ and littermate controls mice. The blue is DAPI (nuclei), the red is LAMININ A/C (Alexa Fluor 647, nuclear envelope), and the green is MYC (Alexa Fluor 488). Scalebar 30 microns (µm). (G) MYC staining Mean Fluorescence Intensity (MFI) average in nuclear and cytoplasmic compartments of MycT58N/+and Myc+/+ mice showing increase cytoplasmic MYC signal in MycT58N/+ (two-tail t test, ***p<0.001). (H) Cytoplasmic to nuclear ratio of MFI MYC signal from (G) (two-tail t-test, **p<0.01). (I) Bar-graph of aggregation propensity of MYCT58N proteins compared to MYC wildtype (two-tail t-test, **p<0.01), as detected using PROTEOSTAT. (J-L) Number of stem cells and progenitor cells per femur of MycT58N/+and Myc+/+detected by flow cytometry in the bone marrow of moribund MycT58N/+mice at takedown. Age-matched littermate controls were taken down and analyzed side-by-side for comparison (*=p<0,05, all other comparison not significant). (M) Kaplan-Meier curve for MycT58N/+ secondary tumors transplant (n = 5 from 2 separate donors). (D-F) Flow cytometry analysis showing the distribution of hematopoietic progenitor cells.
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Missense Mutations in Myc Box I Influence Nucleocytoplasmic Transport to Promote Leukemogenesis
Supplementary Figure 6. (A-B) Bar graphs of the distribution of white blood cells (WBC) counts (1000/microliter), hemoglobin (Hb, grams/deciliter) and platelets (1000/microliter) in MycT58N/+ and Myc+/+mice at 8 and 12 weeks of age. None of the differences are statistically significant. (C) Bar graphs of the distribution of weight in 8-12 weeks old males (left panel) and females (right panel) MycT58N/+and Myc+/+showing no significant differences across genotype. (D-E) Bar graphs of the distribution of stem and progenitor cells in the bone marrow compartment of 6-8 weeks old MycT58N/+ and Myc+/+ as determined by flow cytometry analysis. None of the differences are statistically significant. (F) Confocal images of HSPCs isolated from healthy, 6 months old, MycT58N/+ and littermate controls mice. The blue is DAPI (nuclei), the red is LAMININ A/C (Alexa Fluor 647, nuclear envelope), and the green is MYC (Alexa Fluor 488). Scalebar 30 microns (µm). (G) MYC staining Mean Fluorescence Intensity (MFI) average in nuclear and cytoplasmic compartments of MycT58N/+and Myc+/+ mice showing increase cytoplasmic MYC signal in MycT58N/+ (two-tail t test, ***p<0.001). (H) Cytoplasmic to nuclear ratio of MFI MYC signal from (G) (two-tail t-test, **p<0.01). (I) Bar-graph of aggregation propensity of MYCT58N proteins compared to MYC wildtype (two-tail t-test, **p<0.01), as detected using PROTEOSTAT. (J-L) Number of stem cells and progenitor cells per femur of MycT58N/+and Myc+/+detected by flow cytometry in the bone marrow of moribund MycT58N/+mice at takedown. Age-matched littermate controls were taken down and analyzed side-by-side for comparison (*=p<0,05, all other comparison not significant). (M) Kaplan-Meier curve for MycT58N/+ secondary tumors transplant (n = 5 from 2 separate donors). (D-F) Flow cytometry analysis showing the distribution of hematopoietic progenitor cells.
- Open Access
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data S8 from Missense Mutations in Myc Box I Influence Nucleocytoplasmic Transport to Promote Leukemogenesis
Supplementary Data S8 Graph Based Cluster Biomarkers
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S8 from Missense Mutations in Myc Box I Influence Nucleocytoplasmic Transport to Promote Leukemogenesis
Supplementary Data S8 Graph Based Cluster Biomarkers
- Open Access
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Missense Mutations in Myc Box I Influence Nucleocytoplasmic Transport to Promote Leukemogenesis
Supplementary Figure 5: (A-B) Confocal images of cytospins of patient-derived AML cells from bone marrow at diagnosis, with MYC mutations (A) and without MYC mutations (B). MYC (antibody 9,402) is in green, LAMININ A/C is red and DAPI is blue. Scalebar: 5 microns.
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Missense Mutations in Myc Box I Influence Nucleocytoplasmic Transport to Promote Leukemogenesis
Supplementary Figure 5: (A-B) Confocal images of cytospins of patient-derived AML cells from bone marrow at diagnosis, with MYC mutations (A) and without MYC mutations (B). MYC (antibody 9,402) is in green, LAMININ A/C is red and DAPI is blue. Scalebar: 5 microns.
- Open Access
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Data from Missense Mutations in Myc Box I Influence Nucleocytoplasmic Transport to Promote Leukemogenesis
Purpose:Somatic missense mutations in the phosphodegron domain of the MYC gene (MYC Box I or MBI) are detected in the dominant clones of a subset of patients with acute myeloid leukemia (AML), but the mechanisms by which they contribute to AML are unknown.Experimental Design:To investigate the effects of MBI MYC mutations on hematopoietic cells, we employed a multi-omic approach to systematically compare the cellular and molecular consequences of expressing oncogenic doses of wild type, threonine-58 and proline-59 mutant MYC proteins in hematopoietic cells, and we developed a knockin mouse harboring the germline MBI mutation p.T58N in the Myc gene.Results:Both wild-type and MBI mutant MYC proteins promote self-renewal programs and expand highly selected subpopulations of progenitor cells in the bone marrow. Compared with their wild-type counterparts, mutant cells display decreased cell death and accelerated leukemogenesis in vivo, changes that are recapitulated in the transcriptomes of human AML-bearing MYC mutations. The mutant phenotypes feature decreased stability and translation of mRNAs encoding proapoptotic and immune-regulatory genes, increased translation of RNA binding proteins and nuclear export machinery, and distinct nucleocytoplasmic RNA profiles. MBI MYC mutant proteins also show a higher propensity to aggregate in perinuclear regions and cytoplasm. Like the overexpression model, heterozygous p.T58N knockin mice displayed similar changes in subcellular MYC localization, progenitor expansion, transcriptional signatures, and develop hematopoietic tumors.Conclusions:This study uncovers that MBI MYC mutations alter RNA nucleocytoplasmic transport mechanisms to contribute to the development of hematopoietic malignancies.
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Missense Mutations in Myc Box I Influence Nucleocytoplasmic Transport to Promote Leukemogenesis
Purpose:Somatic missense mutations in the phosphodegron domain of the MYC gene (MYC Box I or MBI) are detected in the dominant clones of a subset of patients with acute myeloid leukemia (AML), but the mechanisms by which they contribute to AML are unknown.Experimental Design:To investigate the effects of MBI MYC mutations on hematopoietic cells, we employed a multi-omic approach to systematically compare the cellular and molecular consequences of expressing oncogenic doses of wild type, threonine-58 and proline-59 mutant MYC proteins in hematopoietic cells, and we developed a knockin mouse harboring the germline MBI mutation p.T58N in the Myc gene.Results:Both wild-type and MBI mutant MYC proteins promote self-renewal programs and expand highly selected subpopulations of progenitor cells in the bone marrow. Compared with their wild-type counterparts, mutant cells display decreased cell death and accelerated leukemogenesis in vivo, changes that are recapitulated in the transcriptomes of human AML-bearing MYC mutations. The mutant phenotypes feature decreased stability and translation of mRNAs encoding proapoptotic and immune-regulatory genes, increased translation of RNA binding proteins and nuclear export machinery, and distinct nucleocytoplasmic RNA profiles. MBI MYC mutant proteins also show a higher propensity to aggregate in perinuclear regions and cytoplasm. Like the overexpression model, heterozygous p.T58N knockin mice displayed similar changes in subcellular MYC localization, progenitor expansion, transcriptional signatures, and develop hematopoietic tumors.Conclusions:This study uncovers that MBI MYC mutations alter RNA nucleocytoplasmic transport mechanisms to contribute to the development of hematopoietic malignancies.
- Open Access
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data S6 from Missense Mutations in Myc Box I Influence Nucleocytoplasmic Transport to Promote Leukemogenesis
Supplementary Data S6 ChIP-seq MACS peaks
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S6 from Missense Mutations in Myc Box I Influence Nucleocytoplasmic Transport to Promote Leukemogenesis
Supplementary Data S6 ChIP-seq MACS peaks
- Open Access
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Missense Mutations in Myc Box I Influence Nucleocytoplasmic Transport to Promote Leukemogenesis
Supplementary Figure 4. (A) Histogram plot showing the viability (as measured by Acridine Orange/Propidium Iodine stain read on a Cellometer instrument) of control cells, MYCWT, MYCP59Q and MYCT58N expressing cells at before (time 0) and 8 hours after treatment with DRB. None of the difference are statistically significant. (B) Schematic overview of the nascent proteomic analysis experimental setup. (C) Volcano plots of the fold changes in spectral counts of MYC overexpressing (doxycycline treated) vs. control (vehicle treated) cells (Supplementary Data S7). Black dashed lines indicate significance (ANOVA, Dox vs Vehicle, fold changes ± 2, adjp<0.05) (D-E) Volcano plots showing the trends in spectral counts fold changes (x-axis) over 30 minutes of OPP nascent polypeptide labeling for cluster 3 genes (D) and for the genes in figure 4A (E). Comparisons are MBI MYCMUT*Dox vs MYCWT*Dox. Red dashed lines indicate significance.
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Missense Mutations in Myc Box I Influence Nucleocytoplasmic Transport to Promote Leukemogenesis
Supplementary Figure 4. (A) Histogram plot showing the viability (as measured by Acridine Orange/Propidium Iodine stain read on a Cellometer instrument) of control cells, MYCWT, MYCP59Q and MYCT58N expressing cells at before (time 0) and 8 hours after treatment with DRB. None of the difference are statistically significant. (B) Schematic overview of the nascent proteomic analysis experimental setup. (C) Volcano plots of the fold changes in spectral counts of MYC overexpressing (doxycycline treated) vs. control (vehicle treated) cells (Supplementary Data S7). Black dashed lines indicate significance (ANOVA, Dox vs Vehicle, fold changes ± 2, adjp<0.05) (D-E) Volcano plots showing the trends in spectral counts fold changes (x-axis) over 30 minutes of OPP nascent polypeptide labeling for cluster 3 genes (D) and for the genes in figure 4A (E). Comparisons are MBI MYCMUT*Dox vs MYCWT*Dox. Red dashed lines indicate significance.
- Open Access
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data S3 from Missense Mutations in Myc Box I Influence Nucleocytoplasmic Transport to Promote Leukemogenesis
Supplementary Data S3 from Missense Mutations in Myc Box I Influence Nucleocytoplasmic Transport to Promote Leukemogenesis
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S3 from Missense Mutations in Myc Box I Influence Nucleocytoplasmic Transport to Promote Leukemogenesis
Supplementary Data S3 from Missense Mutations in Myc Box I Influence Nucleocytoplasmic Transport to Promote Leukemogenesis
- Open Access
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data S5 from Missense Mutations in Myc Box I Influence Nucleocytoplasmic Transport to Promote Leukemogenesis
Differentially Expressed Genes in Bulk RNA sequencing
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S5 from Missense Mutations in Myc Box I Influence Nucleocytoplasmic Transport to Promote Leukemogenesis
Differentially Expressed Genes in Bulk RNA sequencing
- Open Access
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data S4 from Missense Mutations in Myc Box I Influence Nucleocytoplasmic Transport to Promote Leukemogenesis
Gene Ontology analysis of Cluster 3 genes
- 15 August 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S4 from Missense Mutations in Myc Box I Influence Nucleocytoplasmic Transport to Promote Leukemogenesis
Gene Ontology analysis of Cluster 3 genes